A core formulation technology validated in humans, on a path that pays its own way.
The biggest shifts in medicine are towards larger, more complex molecules, and delivery and stability are the key bottlenecks holding them back. reThink64 has a core technology that clears that bottleneck, and a commercial model where near-term use cases and revenue fund the real-world data that de-risks the larger pipeline opportunities.
Own the formulation layer enabling the next generation of medicine.
We are not betting on a single molecule. We are building the unlocking technology for a new era of molecules in health and medicine.
A core technology, applied across use cases
One formulation system serves proteins, peptides and RNA across multiple tissues. Value compounds with each molecule it enables rather than riding on one program.
Evidence, not extrapolation
We show the platform working in human tissue early. That retires the risk that sinks most delivery technologies, and it does so years ahead of a conventional timeline.
Revenue before the clinic
Partnering, licensing and early commercialization in less regulated use cases generate revenue and real-world data at the same time, so the science advances without depending exclusively on continual investment.
Three lead markets. All face the formulation wall.
Our current and prospective clients operate in these markets. Delivery and stability problems stymie progress in each, which is what lets our core technology address all three.
Peptides
Large molecules limited by poor tissue penetration.
Unstable actives
Oxidation- and hydrolysis-prone actives that degrade in weeks at room temperature.
Immunomodulators
Localized immune therapies are wanted, but systemic exposure brings side effects.
Global annual sales in each market, from public market research (2024 to 2025). Listed separately, not summed.
Commercializable from day one. Initial applications in skincare and dermatology fund the data that de-risks the later pipeline.
Most biotechs build the whole drug product and wait the better part of a decade for revenue. We reached our first paid engagement in year four by developing enabling formulations for partners’ commercial actives. Each partnership produces revenue and data that supports and de-risks the next application.
Commercial-ready chemistry
We work with approved materials and existing molecules, not new chemical entities.
Paid partner codevelopment
Skincare and dermal drug developers pay us to solve stability and delivery, which generates early revenue.
Licensing and royalties
Staged milestones lead to licensing deals and recurring royalty streams.
Growing real-world data set
Funded skin model and consumer data sets de-risk and fast-track the technology for more advanced indications.
Partnerships currently in place.
Across skincare, longevity and contract manufacturing.
Built and backed by people who have done it before.
Serial founders and scientists with deep experience in large-molecule biotech, delivery and commercialization, and prior exits.
Built and backed at
If this is your thesis, we should talk.
We are always happy to walk through the platform, the data and the business model in more detail. Let’s chat.
Get in touch